We also found that the combination of anti-DKK2 can be used with anti-VEGFR in a mouse CRC model and notably DKK2-blockade can augment anti-tumor efficacy of sub-optimal dosage of anti-VEGFR by further reducing tumor angiogenesis and enhancing anti-tumor immunity. The gene discussed is KDR; the disease is colorectal carcinoma.